Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 6/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31437246 | 1.00 | S1PR4 (0.44) | S1PR4KDM4ELMNAMAPTCYP1A2 | |
| SCHEMBL4858597 | 0.85 | S1PR4 (0.43) | S1PR4KDM4ELMNAMAPTCYP1A2 | |
| SCHEMBL34475296 | 0.81 | HTR7 (0.47) | KDM4ELMNAMAPTCYP1A2CYP3A4 | |
| SCHEMBL24538043 | 0.81 | HTR7 (0.47) | KDM4ELMNAMAPTCYP1A2CYP3A4 | |
| SCHEMBL570791 | 0.80 | S1PR4 (0.45) | S1PR4KDM4ELMNAMAPTCYP1A2 | |
| SCHEMBL25236185 | 0.79 | KDM4E (0.43) | KDM4ELMNAMAPTCYP1A2CYP3A4 | |
| SCHEMBL31022737 | 0.79 | KDM4E (0.43) | KDM4ELMNAMAPTCYP1A2CYP3A4 | |
| SCHEMBL30557100 | 0.78 | KDM4E (0.35) | KDM4ELMNAMAPTCYP1A2CYP3A4 | |
| SCHEMBL26118784 | 0.78 | KDM4E (0.35) | KDM4ELMNAMAPTCYP1A2CYP3A4 | |
| SCHEMBL9476261 | 0.78 | PLCG1 (0.35) | MAPTSMN1; SMN2ALOX5APFEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2025-10-02 | — | — | US | disclosed |
| EP-4526293-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Repare Therapeutics Inc. (CA) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023220831-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-11-23 | — | — | WO | disclosed |
| US-20230174536-A1 | NOVEL COMPOUNDS FOR DIAGNOSIS | AC IMMUNE SA (CH) | 2023-06-08 | — | — | US | disclosed |
| EP-1516874-B1 | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation | DOW AGROSCIENCES LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-RE39991-E1 | Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation | DOW AGROSCIENCES LLC (US) | 2008-01-01 | — | — | US | disclosed |
| US-5716971-A | FOR TREATMENT OF ANGINA PECTORIS AND HYPERTENSION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0623597-B1 | Pyridine derivatives, with potassium channel opening activity | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-10-22 | — | — | EP | disclosed |
| EP-0623597-A1 | Pyridine derivatives, with potassium channel opening activity | Takeda Chemical Industries, Ltd. (JP) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CSNK1A1, CSNK1G1, CSNK2A1 | S1PR4 4126/4885KDM4E 2698/4885LMNA 3295/4885 |
| US-20230174536-A1 | NOVEL COMPOUNDS FOR DIAGNOSIS | SNCA, PARK7, SLC6A3 | S1PR4 1346/4885KDM4E 4851/4885LMNA 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.